Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novavax Eyes Asia Expansion As Vaccines Portfolio Progresses

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.S. vaccines company Novavax is making inroads into Asia and developing markets with its influenza and RSV vaccines.

You may also be interested in...



South Korea's LG Takes Shot At Vaccines Via In-licensing Deal With U.S. Novavax

SEOUL - South Korea's LG Life Sciences said next year it will start building a production plant in Osong, south of the capital city of Seoul, to produce cell-culture influenza vaccines based on the virus-like particle technology in-licensed from Novavax of the U.S

South Korean Government To Build New Flu Vaccine Plant As Part Of Campaign For "Vaccine Independence" From Global Giants

SEOUL - To avoid a recurrence of last year's challenge to secure flu vaccines during the A/H1N1 pandemic, South Korea's government has initiated a drive to bolster the nation's independent capacity to produce these vaccines

Novavax Looks To Increase Runway Through Strategic Alliance With India’s Cadila Pharma

A recently announced three-prong partnership with India's Cadila Pharmaceuticals should enable Novavax to pay off $22 million in convertible debt due in July and still have about one year's worth of operating cash, the vaccine maker's chief executive, Rahul Singhvi, said in an interview

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel